Tag Archives: cardiovascular disease

Most people think diabetes-related blood vessel damage begins only after years of high blood sugar. However, scientists are uncovering evidence that injury may start much earlier, in a structure so thin it cannot be seen during a routine medical exam. This microscopic layer, known as the endothelial glycocalyx, acts as …

For many people with diabetes, lowering LDL cholesterol is just as important as controlling blood sugar. However, not everyone reaches their cholesterol goals with statins alone, and injectable PCSK9 inhibitors can be inconvenient or intimidating. Now, a new option has arrived. The FDA has approved the first oral PCSK9 inhibitor, …

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

Diabetes often develops silently for years before blood sugar levels become high enough for a diagnosis. What if tiny biological packages circulating in the bloodstream could reveal those hidden changes long before symptoms appear? Researchers are increasingly studying how exosomes may serve as biomarkers for diabetes because these microscopic messengers …

For years, artificial sweeteners have been promoted as an important strategy for reducing sugar intake in people with diabetes. They help lower carbohydrate intake, reduce post-meal glucose spikes, and support weight management without adding calories. However, recent research has challenged the long-held assumption that all non-nutritive sweeteners are metabolically neutral. …

Blood pressure control remains one of the most powerful tools for reducing cardiovascular and kidney complications in people with diabetes. While clinicians have traditionally focused on achieving targets below 140/90 mmHg, recent evidence and the 2026 American Diabetes Association Standards of Care support a more intensive approach for selected high-risk …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …

Diabetes is a serious disease that affects millions of people worldwide. It is associated with an increased risk of cardiovascular disease and other complications. To reduce this risk, various lipid-lowering agents have been developed to lower cholesterol levels and reduce the risk of cardiovascular disease. This article reviews the current …